TKI including Axitinib, Sorafenib, Sunitinib, Pazopanib, and Tivozanib inhibit VEGF signaling by targeting the intracellular domain of the VEGFR; however, mTOR–raptor signaling is a potential target for antitumor therapy and mTOR inhibitors are currently under investigation for the treatment of various human cancers [44]. Here, RPTOR is linked to cancer.